Patents by Inventor David Lebwohl

David Lebwohl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR IN VIVO EDITING OF A LIVER GENE
    Publication number: 20250269062
    Abstract: The first systemic administration of a CRISPR/Cas9-based therapeutic for in vivo editing in a clinical trial is described. Described herein are methods for in vivo editing of a liver gene by systemically administering a lipid nanoparticle composition comprising an mRNA encoding a Cas nuclease and a guide RNA that targets the gene. For example, disclosed herein are methods for in vivo editing of a transthyretin gene by systemically administering a lipid nanoparticle composition comprising an mRNA encoding a Cas nuclease and a guide RNA that targets the TTR gene. Assessment of biosafety metrics and clinical efficacy metrics, as well as methods of treatment, are also described herein.
    Type: Application
    Filed: June 22, 2022
    Publication date: August 28, 2025
    Inventors: David LEBWOHL, Michael MAITLAND, Mark STROH, Yuanxin XU
  • COMBINATION THERAPIES
    Publication number: 20240075136
    Abstract: Combination therapies are disclosed. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.
    Type: Application
    Filed: December 5, 2022
    Publication date: March 7, 2024
    Inventors: David Lebwohl, Malte Peters
  • Combination therapies
    Patent number: 11344620
    Abstract: Disclosed is a combination comprising an immunomodulator and a second therapeutic agent for use in treating cancer, wherein the immunomodulator is an inhibitor of an immune checkpoint molecule or an activator of a costimulatory molecule, or a combination thereof; and the second therapeutic agent is chosen from one or more of: 1) a c-MET inhibitor; 2) a CDK4/6 inhibitor; 3) a PI3K inhibitor; 4) a BRAF inhibitor; 5) an FGFR inhibitor; 6) a MEK inhibitor, or 7) a BCR-ABL inhibitor. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: May 31, 2022
    Assignee: Novartis AG
    Inventors: David Lebwohl, Malte Peters
  • Combination therapies of EGFR inhibitors
    Patent number: 9993551
    Abstract: Combination therapies are disclosed. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: June 12, 2018
    Assignee: Novartis AG
    Inventors: David Lebwohl, Malte Peters
  • COMBINATION THERAPIES OF EGFR INHIBITORS
    Publication number: 20170304443
    Abstract: Combination therapies are disclosed. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.
    Type: Application
    Filed: September 11, 2015
    Publication date: October 26, 2017
    Inventors: David Lebwohl, Malte Peters
  • COMBINATION THERAPIES
    Publication number: 20170296659
    Abstract: Disclosed is a combination comprising an immunomodulator and a second therapeutic agent for use in treating cancer, wherein the immunomodulator is an inhibitor of an immune checkpoint molecule or an activator of a costimulatory molecule, or a combination thereof; and the second therapeutic agent is chosen from one or more of: 1) a c-MET inhibitor; 2) a CDK4/6 inhibitor; 3) a PI3K inhibitor; 4) a BRAF inhibitor; 5) an FGFR inhibitor; 6) a MEK inhibitor, or 7) a BCR-ABL inhibitor. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.
    Type: Application
    Filed: September 11, 2015
    Publication date: October 19, 2017
    Inventors: David Lebwohl, Malte Peters
  • COMBINATION THERAPIES OF ALK INHIBITORS
    Publication number: 20170281624
    Abstract: A method of treating a cancer in a subject is disclosed, comprising administering to the subject an immunomodulator and a second therapeutic agent, wherein: (i) the immunomodulator is chosen from one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule, and (ii) the second therapeutic agent is LDK378, thereby treating the cancer.
    Type: Application
    Filed: September 11, 2015
    Publication date: October 5, 2017
    Applicant: Novartis AG
    Inventors: Malte Peters, David LEBWOHL, Jeffrey SCOTT, Nanxin LI, Yvonne LAU
  • Neuroendocrine Tumor Treatment
    Publication number: 20170128425
    Abstract: A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug.
    Type: Application
    Filed: January 13, 2017
    Publication date: May 11, 2017
    Inventors: Peter Wayne Marks, David Lebwohl
  • Neuroendocrine Tumor Treatment
    Publication number: 20150148294
    Abstract: A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 28, 2015
    Applicant: Novartis AG
    Inventors: Peter Wayne Marks, David Lebwohl
  • Neuroendocrine tumor treatment
    Patent number: 9006224
    Abstract: A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug.
    Type: Grant
    Filed: November 20, 2006
    Date of Patent: April 14, 2015
    Assignee: Novartis AG
    Inventors: Peter Wayne Marks, David Lebwohl
  • TUBEROUS SCLEROSIS TREATMENT
    Publication number: 20100305150
    Abstract: Rapamycin derivatives for use in the treatment of neurocutaneous disorders.
    Type: Application
    Filed: January 31, 2007
    Publication date: December 2, 2010
    Inventors: William Berg, John Benedetto, Ingrid Elmroth, Heidi Lane, David Lebwohl, William Sellers, Michael Stumm
  • Neuroendocrine Tumor Treatment
    Publication number: 20080255029
    Abstract: A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug.
    Type: Application
    Filed: November 20, 2006
    Publication date: October 16, 2008
    Applicant: NOVARTIS AG
    Inventors: Peter Wayne Marks, David Lebwohl
  • Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
    Patent number: 7008936
    Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative diseases.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: March 7, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Maurizio Voi, David Lebwohl
  • Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
    Publication number: 20040024032
    Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative diseases.
    Type: Application
    Filed: June 12, 2003
    Publication date: February 5, 2004
    Inventors: Maurizio Voi, David Lebwohl